Over the last 20 years there has been a considerable increase in the number of tests made available to the obstetrician by the biochemistry laboratory. Notable among these have been tests of fetoplacental function. These were intended to identify those pregnancies in which the fetus was at serious risk and where immediate intervention would result in saving life. Retrospective studies have confirmed the ability of many of these tests to be useful in this regard, and these have been well reviewed.' However, very few studies have investigated whether fetoplacental function tests are of use prospectively.s" It is apparent that to predict sudden fetal risk the tests must be performed at regular, frequent intervals. The majority of obstetric departments request these parameters, at most, once or twice each week in the last trimester of pregnancy and may be alerted to these sudden events at too late a stage to provide any effective remedy. The costs of performing fetoplacental function tests daily on every pregnant patient, or on every 'high-risk' pregnancy, to detect the less than 2 % of fetal deaths which occur have appeared prohibitive. Instead, the obstetric departments, with the cooperation of the chemical pathology laboratories, have continued the established pattern of sampling. The justification for this approach has been the pressure to lower perinatal Pregnant women attending the Victoria Hospital, 12
Total score of 4 or greater = 'abnormal birth'. In addition, information concerning the outcome of pregnancy was collected. This included details of week of gestation at delivery, type of delivery, birthweight, and condition of the placenta. An assessment of the pregnancy was also made at this time to classify each birth as 'normal' or 'abnormal' (Table 2) .
Results
The distribution of results into the eight groups by prospective classification is given in Table 1 . It may be seen that 47 %ofthe patients' results are classified as abnormal and, of these, there are 36 %where no intervention was deemed necessary on clinical grounds. The retrospective classification of these results agreed closely with the prospective classification, the difference being that four patients were transferred from group 3 to group 7. This fact indicates that, to a high degree, the results were interpreted by the clinical staff in the previously defined manner. Table 3 shows the numbers and types of abnormal tests for each group; 50 % of the abnormal tests are HPL, 28 % are TE, and 22 %are CAS. When only one test is abnormal, there are no Blackpool, had blood samples taken for human placental lactogen (HPL), total oestriol (TE), and cystine aminopeptidase activity (CAS) assays at weekly or twice-weekly intervals. Only those patients who had at least six consecutive samples, the final sample being collected within three days before delivery, were included. Adherence to these criteria resulted in 166 patients remaining for study.
HPL and TE levels were assayed using kit methods available from the Radiochemical Centre, Amersham (HPL immunoassay kit-IM.68 and Oestriol (total) RIA kit-IM.82, respectively). CAS was assayed using a Vitatron AKES reaction rate analyser with S-benzyl cysteine p-nitroanilide as substrate.
Reference values for the HPL data were taken from previous work,? while those for TE were as supplied in the assay kit instructions. These latter values compared well with those obtained from a relatively small number of patients (65) assayed during the kit evaluation period. The method used for the measurement of serum CAS activity in previous work? was that of van Oudheusden," employing L-cystine bis p-nitroanilide as substrate. This substrate had a low solubility in aqueous solvents and was used at suboptimal concentrations, and the method was difficult to automate. For these reasons, this method was compared with an .automated version of that described by Tovey et al., 9 Chapman et al.,lD and Durham.P using S-benzyl cysteine p-nitroanilide as substrate at a final reaction mixture concentration of 0'7 rnmol/l, The reaction was monitored at a wavelength of 405 nm and was performed at a temperature of 37°C and a pH of7' 2. The concomitant assay of 80 sera by both methods led to the establishment of the following linear relationship:
CAS activity (automated) = CAS activity (van Oudheusden) x 26· 3 (with a correlation coefficient of 0,99).
The reference values obtained in previous work? were converted to reference values for the automated method using this relationship.
Results for the three fetoplacental function tests were assessed by the obstetricians as pregnancy advanced and were acted upon accordingly. After delivery the results were assessed again (DMcD) and compared with the previous assessment. The results were divided into eight groups, depending on the number of sets of results that were abnormal and whether any action had been taken (Table 1) . (NB. A set (If results is a consecutive series of results of one assay on one patient.) An abnormal set of results was defined as results outside the appropriate reference range, or three consecutive results level or Table 2 , the number of abnormal births in each group was calculated (Table 4 ). It may be seen that there is an increase in the percentage of abnormal births as the number of abnormal tests increases, and that the percentage of abnormal births is lower in those groups where no action was considered necessary on clinical grounds. It should be noted that 6·8 %of the 6 show the condition of the placenta at birth, the time of delivery, and the type of delivery. The condition of the placenta appears worse in those groups where action was taken, but even in the normal groups there is a high percentage of unhealthy placentas. As expected, there is an increased percentage of births before 38 weeks gestation in those groups where intervention was considered necessary. In these groups there is an increased number of deliveries by caesarean section compared with those groups where delivery occurred at between 38 and 42 weeks gestation but intervention was considered necessary.
The mean birthweight for each group and the birthweight expressed as a percentage of the mean birthweight for the week of gestation for normal babies-'' are shown in Table 7 . As the number of abnormal tests increase, the mean birthweight decreases. This is more clearly demonstrated by the calculated value-'percentage of the normal mean birthweight for the week of gestation.' Table 5 Condition ofthe placenta and time ofdelivery for all patients HPL   2  9  0  9  3  7  7  9  4  8  3  82  9  5  0  0  0  0  6  0  1 0  1 0  0   TE   0  2  0  5  3  7  9  4  0  4  3  82  7 
as 'at risk' by the test result, in relation to all'at risk' patients in the test population
Predictive value = number of patients diagnosed as 'at risk' by the test result who were 'at risk", in relation to the total number of patients with abnormal results Relative risk = ratio of the percentage of patients diagnosed as being "at risk', who were 'at risk', to the percentage of patients who were diagnosed as being healthy, but who were found to be 'abnormal'. A relative risk of 1 indicates no selection for fetal risk, whereas above 1 the risk increases. were classified as normal or abnormal by predetermined definitions, and patients were allocated to one of eight groups, depending on the number of abnormal results and whether these were acted upon by the obstetrician. Interestingly, no intervention was considered necessary for approximately onethird of the patients with abnormal results. In groups 3,5, and 7, where no action was considered necessary the proportion of abnormal births was lower than in groups 4, 6, and 8 where action was taken. Consideration of all abnormal result sets ignored shows that 18% were from patients who produced an 'abnormal baby'. This may be compared with the 54% 'abnormal births' in groups 4,6, and 8. A study of Tables 5, 6, and 7 confirms that, in relation to a birthweight and condition of placenta, groups 3, 5, and 7 have a lower percentage of abnormalities compared to groups 4, 6, and 8. Although it is appreciated that impressions of placental condition do not reflect placental function, it is apparent from these figures that the clinical judgment which has been used to evaluate the patient's condition has been considered more accurate than the information gained from the abnormal fetoplacental function test results. Tables 4 and 7 show that the percentage of abnormal births increases and the mean birthweight for the week of gestation decreases as the number of abnormal result sets per group increase. It should be stressed that the birthweight expressed as a percentage of the normal mean birthweight for the week of gestation also decreases. This indicates that the effect is a true reflection of a 'small-for dates' baby
Discussion
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Test Table 8 shows the numbers of true positive, false positive, true negative, and false negative results for each group. From these figures the sensitivity and specificity of each test, the relative risk of having an abnormal result, the predictive value of each test, and the prevalence of diagnosed abnormality in relation to the prevalence of true abnormality were calculated.P These are shown in Table 9 . In addition, the predictive value, the prevalence of true abnormality, and the prevalence of diagnosed abnormality were compared between the groups, as shown in Table 10 .
and not solely the result of an early delivery. It appears that abnormal fetoplacental function test results reflect an increased risk of an 'abnormal birth' or a low birthweight, However, from the figures given in Table 9 , it is evident that this is not always the case. The sensitivity and specificity figures indicate a poor false positive and false negative detection rate. Figures for the predictive value of the tests indicate that only approximately 50 % of patients who were diagnosed as potential producers of 'abnormal births' actually gave 'abnormal births'. A comparison of prevalence of true 'abnormality' with prevalence of diagnosed 'abnormality' in Table 10 indicates that serum HPL levels overdiagnose abnormal births in each group, serum TE levels in groups 3, 4, 5, and 6 approximate the prevalence of true 'abnormality' but overdiagnose in groups 7 and 8, while serum CAS levels underdiagnose in groups 3 and 4 but overdiagnose in groups 5, 6, 7, and 8.
In this study the obstetrician has been given the results of three fetoplacental function tests which have then been classified in varyingdegreesof abnormality. Based upon previous work, the abnormal biochemical test results could have indicated the possibility of impending death in utero. 7 The decision to intervene in a particular pregnancy is taken on biochemical and clinical grounds, the latter comprising fetal heart beat, ultrasonic scan, and kick chart measurements and palpation to assess gestational age. It is apparent from this work that abnormal fetoplacental function tests have been poor indicators of abnormal births and have, quite correctly, been awarded a minor role in the management of these patients. The increasing number of abnormal tests in a patient reflects the possibility of a decreased birthweight and of an unhealthy-looking, but probably functionally capable, placenta. The definition of 'abnormal birth' may be criticised as being too strict because all of the babies were born alive. This does not matter so long as it reflects those patients who had an increased risk of fetal distress. Equally, it is possible that the patients were not randomly selected from the antenatal population but were biased towards an 'at risk' group. This is reflected in the fact that 47 % of the group had at least one abnormal result set. If the patients were not randomly selected, then the statistics given in Tables 9 and 10 may not be extrapolated to reflect the typical antenatal population. This does not detract from the interpretation of these statistics, however, and it is apparent from these figures that the biochemical indices studied give misleading information. If fetoplacental function tests solely are considered as indices of fetal risk prediction, then it Mc Oowell, Oliver, and Best is apparent that they have a limited role, at best being used to alert the obstetrician to an increased risk of an 'abnormal birth'. When these tests are considered as part of the present spectrum of clinical tests, then their role becomes minor. The justifications for performing expensive biochemical tests to predict the very low percentage of fetal deaths appear limited. If clinical tests have superseded biochemical tests in the last trimester of pregnancy, as is suggested by this work, then chemical pathology departments must consider carefully whether this service should be continued.
